Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_assertion type Assertion NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_head.
- NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_assertion description "[To determine the contribution of C5a to the pathology displayed by this model of ALS, rats were administered an orally active, selective C5aR antagonist (PMX205; 1 mg/kg/day, oral).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_provenance.
- NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_assertion evidence source_evidence_predicted NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_provenance.
- NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_assertion SIO_000772 19050293 NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_provenance.
- NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_assertion wasDerivedFrom rgd-20150221 NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_provenance.
- NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_assertion wasGeneratedBy ECO_0000218 NP47725.RAYkeHrpSl3fRLTHGcaZnxQJhtDEpOq3n-FcvTlrGggbc130_provenance.